NCT02730312View on ClinicalTrials.gov

PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

August 31, 2016

Primary Completion Date

September 30, 2021

Study Completion Date

September 30, 2021

Conditions
Acute Myelogenous LeukemiaB-cell Acute Lymphoblastic LeukemiaBlastic Plasmacytoid Dendritic Cell NeoplasmChronic Myeloid Leukemia, Blast Crisis
Interventions
BIOLOGICAL

XmAb14045

Administered IV weekly up to 8 weeks, with or without step-up dosing

Trial Locations (9)

30308

Emory University Hospital Midtown, Atlanta

30322

Winship Cancer Institute, Emory University, Atlanta

30342

Blood and Marrow Transplant Group of Georgia, Atlanta

Northside Hospital, Atlanta

32224

Mayo Clinic Jacksonville, Jacksonville

43210

Wexner Medical Center at The Ohio State University, Columbus

60637

The University of Chicago Medical Center, Chicago

77030

The University of Texas MD Anderson Cancer Center, Houston

98104

Swedish Cancer Institute, Seattle

Sponsors

Collaborators (1)

ICON Clinical Research
All Listed Sponsors
collaborator

ICON Clinical Research

INDUSTRY

lead

Xencor, Inc.

INDUSTRY